93 results about "Hemostatic Agent" patented technology

The invention relates to a hemostasis method scheduling and priority ranking method in war wound first aid. The method comprises the following steps: acquiring key parameters of a wounded person based on multi-source data including visual images, wearable physiological monitoring and voice input, wherein the key parameters include the bleeding amount, the wound part, the bleeding speed and vital signs; constructing a hemostasis urgency degree evaluation model, and mapping each wounded person into a hemostasis urgency degree index BUI; each BUI index is used as one of input parameters for subsequent scheduling and sorting, so that the system is driven to start by injury conditions, and a basic priority sequence is established; the method comprises the following steps: carrying out classification modeling on common hemostasis methods including tourniquets, hemostatic gauze, injection type hemostatic agents and air pressure hemostasis equipment, and establishing an applicable condition matrix; constructing a scheduling rule engine, and dynamically recommending a matched hemostasis method set in combination with the BUI index of the wounded, the wound part, the means adaptability and the risk factor; and a scheduling algorithm is utilized to distribute hemostasis means combination and sequence for each wounded.

A novel active agent-eluting hemostatic agent and methods of use and manufacture thereof are presented. A polymer, such as gelatin, is used as the base for a hemostatic agent. The gelatin is crosslinked with a chemical crosslinker, such as a carbodiimide, in the presence of an active agent. The active agent may be an anesthetic or antimicrobial, such as an antibiotic. The novel process allows for the active agent to be both covalently bound to the gelatin as well as be trapped within cages in the gelatin that are formed from the crosslinking. This dual measure allows for controlled and sustained release of the active agent from the hemostatic agent to reduce surgical site infections.

The invention discloses a self-gelation fluid gelatin hemostatic and a preparation method thereof. The self-gelation fluid gelatin hemostatic is a paste hemostatic prepared by sequentially carrying out primary cross-linking gelation, secondary thermal cross-linking and hydration on phenylboronic acid modified gelatin and a cross-linking agent containing a diol structure. And due to primary cross-linking gelatinization, the composite material has a self-gelatinized network structure based on boric acid ester bond connection. The self-gelatinized fluid gelatin hemostatic has double hemostatic mechanisms, gelatin paste can be quickly self-gelatinized and attached in situ for physical plugging after being extruded, and meanwhile, gelatin can activate and accelerate an endogenous hemostatic pathway, so that quick hemostasis is realized. After hemostasis is completed, due to the self-gelation characteristic, fluid gelatin paste which is not infiltrated by blood can be directly clamped and removed through tweezers, the step that traditional fluid gelatin needs to be flushed with normal saline and then is sucked and removed is avoided, and the operation efficiency is improved.

The present invention relates to a paste composition, a biodegradable injectable paste, and a method for producing the same. According to the present invention, the paste composition may offer the convenience of being applied to the application site using one syringe without the need to mix using two syringes immediately before use, by providing a crosslinked hydrogel as a paste phase, as well as biocompatibility, tackiness, and the balance between viscosity and elasticity, and thus is suitable for use in applications, including hemostatic agents, bone fillers, wound dressings, drug carriers, tissue repair materials, skin soothing agents, moisturizing agents, anti-inflammatory agents, and anti-atopic agents.

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate and a hemostatic agent. The substrate includes a first piece and a second piece that is joined with the first piece. The first piece includes the hemostatic agent and the second piece includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.

The invention relates to the technical field of first-aid equipment, and discloses single-person self-rescue equipment which comprises at least one equipment shell, a blood pump, a built-in blood tank and a control chip are installed in the equipment shell, and a silica gel blood biting ring containing hemostatic is installed on the edge of the bottom of the equipment shell; a blood monitor body, a power supply battery, an external blood tank and an autologous blood tank are matched with the equipment shell; the external blood tank and the autologous blood tank are integrally arranged in a waist-loaded container, an external guide channel and a blood transfusion channel are further formed in the equipment shell, and the blood transfusion channel extends out of a port outside the equipment shell and can be connected with a preset transfusion needle head through a corresponding flexible telescopic channel pipe. By means of the device, bleeding can be stopped in time, blood collection and transfusion can be achieved, meanwhile, autoblood prepared in the autoblood tank in advance can be supplemented and transfused back into the body of a wounded person, and the survival probability of the wounded person can be greatly increased under the emergency situation.

The present invention relates to nasal formulations for non-invasive delivery comprising a hemostatic agent and a super absorbent polymer in a powder form, and to uses of said formulations for preventing and / or treating epistaxis.

The invention discloses a hemostatic PW4-FIDD-SUP as well as a preparation method and application thereof, and belongs to the technical field of medicines. According to the preparation method, different phase-state preparations are prepared by performing different phase-state resolution on the wine-processed radix scutellariae and fructus gardeniae matched water decoction, and the difference condition among different preparations is determined through physical property detection, protein and total sugar content detection and component analysis. The invention also determines that the internal dialysis fluid-supernatant (PW4-FIDD-SUP) of the wine-processed radix scutellariae and fructus gardeniae matched water decoction has a remarkable effect in the aspects of regulating and controlling body functions and preventing and treating gastrorrhagia, and the PW4-FIDD-SUP has the effects of diminishing inflammation and relieving pain. The research result of the invention provides a new strategy for the development of a novel preparation of the fructus gardeniae stir-fried with wine radix scutellariae, and provides a theoretical basis for the research of pharmacodynamic substances of the fructus gardeniae stir-fried with wine radix scutellariae.

A carboxylic acid-type lipid can accelerate adhesion or aggregation of platelets even if the carboxylic acid-type lipid does not carry a protein involved in adhesion or aggregation of platelets or a peptide corresponding to an active site of the protein; a lipid particle and a lipid membrane each include the carboxylic acid-type lipid; and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane. A carboxylic acid-type lipid is selected from carboxylic acid-type lipids represented by formulas (I) to (VI), a lipid particle includes the carboxylic acid-type lipid, a lipid membrane includes the carboxylic acid-type lipid, and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane.

A medicinal composition and a hemostatic agent, exhibiting both excellent hemostatic properties and excellent retention properties over time, and a dispenser with which the medicinal composition or hemostatic agent can be satisfactorily sprayed are provided. The medicinal composition is applied to the surface of an inner lumen of the digestive tract of a living body; the dispenser sprays the medicinal composition and the hemostatic agent, which are powders containing polyacrylic acid and polyvinylpyrrolidone, onto the surface of the inner lumen of the digestive tract; the dispenser comprises a main body and a catheter, the main body having an intake section that draws in air from an exterior of the living body and is configured to expel the air by pressurizing the intake air, a reservoir that receives the medicinal composition, and at least two non-return valves; the catheter has a connecting section that is connected to the reservoir and through which the medicinal composition flows;and the dispenser is configured to spray the medical composition from an end part of the catheter onto the surface of the inner lumen of the digestive tract by expelling air from the receiving section.

An expandable biodegradable hemostatic matrix comprised of oxidized cellulose, and having a density ranging from about 0.8 to about 1.2 gr / cm3 is disclosed herein. The matrix may be expandable to at least 3 times its original volume within 4 sec upon contact with an aqueous solution room temperature. Further disclosed are methods for making the hemostatic matrix as well as method of treating a wound.

The invention relates to a biomedical material, in particular to a multifunctional calcium-phosphorus-based bone wound hemostatic which mainly comprises medical high-purity tricalcium phosphate ceramic particles, monocalcium phosphate powder, disodium dihydrogen pyrophosphate, sodium hydroxide, distilled water and a retarding material, and a first semi-solid and a second semi-solid are prepared from the materials. After mixing, the calcium-phosphorus-based ceramic particles, distilled water and monocalcium phosphate powder form a self-curing reaction for stopping bleeding of bone wounds. In order to adapt to different clinical application scenes, the hemostatic can be designed into two dosage forms, namely a plastic type hemostatic and an injection type hemostatic. The hemostatic provided by the invention has excellent chemical stability and biological safety, strong hemostatic effect, controllable degradation rate, good operability and action convenience, and also has the functions of promoting tissue regeneration, resisting infection and the like.

The invention relates to the technical field of biopsy equipment, and provides a coaxial puncture cannula device, a biopsy needle suite and a using method.The coaxial puncture cannula device is used for being connected with a biopsy needle and comprises a puncture tube body, a liquid injection tube, a liquid outlet tube, a liquid outlet tube, a liquid outlet tube and a liquid outlet tube, and the puncture tube body is provided with a puncture channel; the handle connecting part is arranged on the puncture tube body; the pressing part is connected with the handle connecting part; the liquid injection part is arranged on the pressure applying side of the pressure applying part, and the liquid injection part is used for containing hemostatic; the handle connecting part is used for connecting a handle of the biopsy needle and has a push-in state and a pull-out state; in the push-in state, the handle connecting part pushes the biopsy needle to be inserted into the puncture channel, and the hemostatic in the liquid injection part is not pushed out; and in the pulling-out state, the handle connecting part pulls the biopsy needle out of the puncture channel and drives the pressure applying part to perform transmission so as to push out the hemostatic in the liquid injection part. The problems that in the prior art, the hemostasis operation is long and the hemostasis effect is not ideal due to pressing operation of manual hemostasis are solved.

The embodiments herein provide hemostatic compositions, methods, and kits comprising composite polymer particles. Upon contact with blood or other physiological fluids, the composite particles adsorb fluid and aggregate into a shape-retentive mass that halts bleeding. In certain embodiments, the particles comprise polymers of 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, or combinations thereof. The particles may be used alone or blended with additional hemostatic agents. Methods of inducing hemostasis are provided for diffuse oozing, or surgical, mucosal, organ surface, fragile tissue or traumatic bleeding, including in patients receiving anticoagulant or antiplatelet therapy. Kits comprising sterile packages of composite particles, optionally with applicators, substrates, or sprays, are disclosed. The compositions exhibit intrinsic hemostatic activity and synergistically enhance the performance of conventional hemostats, achieving rapid clotting. After hemostasis is achieved, the compositions remain in situ as a conforming protective layer, reducing the need for additional covering materials and decreasing risk of re-bleeding.

A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

A dressing for use with percutaneous tubes / drains / pins and tracheostomies that is designed to be impermeable to aid in the prevention of leakage of body secretions or fluids and to help prevent microbes from entering the body around the percutaneous device from the outside of the dressing. The dressing includes three layers or more including a layer having antimicrobial, bacteriocidal, or hemostatic agents, a cushioned absorbent layer covered by an outer see through impermeable adhesive layer.

The invention provides alimentary canal hemostatic particles and a preparation method thereof. The alimentary canal hemostatic particles are prepared from components as follows: a hemostatic and an excipient, the hemostatic is prepared from polyacrylic acid, polyethyleneimine and polyoxyethylene; the mass ratio of polyacrylic acid to polyethyleneimine to polyoxyethylene is 1: (1-2): (0.04-1). The hemostatic particles have excellent endoscope catheter conveying performance and can quickly absorb a large amount of water to form hydrogel in situ after being sprayed on a bleeding wound surface, the hydrogel adheres to the tissue surface to form a physical barrier, immediate hemostasis is achieved, meanwhile, the hydrogel formed in situ has excellent adhesion stability and corrosion resistance, and the hemostatic particles have good application prospects. It can be guaranteed that the wound surface is still protected within 72 h after the operation, and the risk of rebleeding is reduced.

The utility model provides a kind of hemostatic gauze ball with hemostatic medicament, it is related to gauze technical field, including sphere and medicament ball, the sphere includes absorbent cotton and gauze mesh belt, the absorbent cotton is spherical, the gauze mesh belt is wrapped in the outside of absorbent cotton, the inside center of absorbent cotton is equipped with inner cavity, the medicament ball is equipped inside inner cavity;The side of the sphere is equipped with hole, and hole is connected to the inside of inner cavity, the inside of hole is equipped with extrusion membrane;The utility model embeds medicament ball in sphere, without extra preparation medicine, when using, only need to lay under sphere to wound, extrude extrusion membrane, press the membrane of broken medicament ball, hemostatic medicament can flow out downwards, carry out quality to wound, it is convenient and fast to operate, it is convenient to use anytime, and when laying, by liquid guide wire core increase the speed of hemostatic medicament in inner cavity flowing downwards gauze mesh belt, with quick-dissolving effect, improve the efficiency of drug action.

A malleable sustained release formulation is created utilizing a local anesthetic wherein the composition is made sustained release by incorporating it into a bovine or porcine hemostatic agent. The composition is malleable enough to fit into a cavity such as a dental cavity and form the shape of the cavity. In addition to providing sustained release of the anesthetic, the composition also provides quicker reduction in bleeding.

The present invention relates to an absorbable internal hemostasis kit and an absorbable internal hemostatic agent, the kit comprising: a first syringe containing a powder mixture including gelatin, thrombin, and calcium chloride; a second syringe containing a mixed solution including a thermo-responsive gel, purified water, polyvinylpyrrolidone, polyethylene glycol, sodium chloride, and a protein extract obtained through a multi-stage decellularization process; and a connector for connecting the first syringe and the second syringe so that the powder mixture and the mixed solution can be combined, wherein the absorbable internal hemostatic agent according to the present invention promotes and activates primary physiological hemostasis through thrombin and provides a secondary physical hemostatic effect by gelling in a temperature range close to body temperature, while also offering additionally wound-healing effects, so as to achieve faster and more effective internal hemostasis.

A method for administering a medicament, the method comprising introducing a fluid into a container (100) containing the medicament, allowing the fluid to flow along a pressure relief channel (231) to an outlet of the container (100), and after the flow rate of the fluid has stabilized, closing the outlet and allowing the fluid to enter a pressure channel (232), flow along the pressure channel (232), exit the pressure channel (232) and push the medicament towards an outlet of the container (100). The method for administering the medicament can deliver the medicament in the container (100) in a more stable and sustained manner and in a more gentle form, effectively avoiding the sudden release of pressure which can cause the medicament to be pushed back by the target tissue and spread over the field of view of the endoscope, thereby allowing more accurate administration of the medicament (e.g. a hemostatic agent), improving the continuity of the endoscopic procedure, improving the hemostatic effect and reducing the time required for the procedure.

The present invention provides hydrophobically modified biopolymers comprising a hydrophobically modified chitosan comprising benzenediol groups, optionally a portion of which is oxidized to the corresponding quinones. The biopolymers exhibit a surprising ability to modulate mucosal adhesion, material cohesiveness, and material hemostatic effects to provide next generation hemostatic agents and the like. Accordingly, in other aspects, the invention provides compositions comprising the modified biopolymers of the invention and methods for the treatment of bleeding and wounds.

The application provides an analgesic hemostatic agent and a preparation method thereof, and belongs to the technical field of medicines. A decellularized material is coupled with a snake venom thrombin and ibuprofen, embedded in a pH-responsive polymer to prepare pH-responsive microspheres, and added into a temperature-sensitive hydrogel together with a traditional Chinese medicine fermentation product to prepare an analgesic hemostatic agent water agent. Porous calcium carbonate microspheres with fixed solid acid are mixed with hydroxyapatite to prepare a spray analgesic hemostatic agent powder, which is used in combination with the analgesic hemostatic agent water agent to prepare the analgesic hemostatic agent. The analgesic hemostatic agent prepared by the application adopts a combination of the powder and the water agent, can better maintain the drug activity, has good hemostatic, analgesic, anti-inflammatory and antibacterial effects, and has a slow and controlled release and a long-acting effect, so that the drug application amount is reduced, the patient compliance is improved, and the analgesic hemostatic agent has a wide application prospect.

The invention belongs to the technical field of dressings, and particularly discloses an antibacterial slow-release dressing and a preparation method thereof.The antibacterial slow-release dressing comprises a carrier and a contact body composed of three contact layers, and raw materials of the first contact layer comprise a microporous contact material, a hemostatic and a first antibacterial agent; raw materials of the first contact layer comprise chitosan, polyurethane, a first antibacterial agent and a one-way isolating membrane, raw materials of the second contact layer comprise chitosan, polyurethane, a second antibacterial agent and a one-way isolating membrane, raw materials of the third contact layer comprise a liquid absorbent, a coagulator and a third antibacterial agent, liquid guiding fibers are further arranged in the three contact layers, and the antibacterial slow-release dressing with a specific function is obtained through preparation of specific components and a specific process. According to the antibacterial slow-release dressing provided by the invention, a multi-layer antibacterial structure with liquid guiding, storing and blocking functions is constructed on the bearing body, so that the antibacterial property of the dressing is obviously improved, and the antibacterial slow-release dressing is applicable to both a large amount of percolate and a small amount of percolate.

The present disclosure provides hydrophobically-modified biopolymers, including hydrophobically-modified chitosans, which comprise benzenediol groups, optionally where a portion are oxidized to the corresponding quinone. The biopolymers demonstrate a surprising ability to tune mucoadhesive properties, material cohesive properties, and hemostatic action of the material, to provide next generation hemostats, among other uses. Accordingly, in other aspects, the disclosure provides compositions comprising the modified biopolymers of the disclosure as well as methods for bleed and wound treatment.

The application relates to the technical field of medical materials, and discloses a hemostatic gel and a preparation method thereof. The hemostatic gel provided by the application comprises the following raw materials in parts by weight: modified chitosan 20-40 parts, hydrated gelatin particles 35-45 parts, fatty acid salt vesicles 5-20 parts, and a crosslinking agent 1-5 parts. The hemostatic gel takes modified chitosan as the main body, combines the hydrated gelatin particles and the fatty acid salt vesicles to form a ternary synergistic system, and is matched with the crosslinking agent, so that the uniformity and mechanical stability of the gel are ensured, the problem of insufficient hemostatic efficiency caused by single component of a traditional hemostatic agent is overcome, and the hemostatic gel has good biocompatibility and degradability, and is especially suitable for a hemostatic application scene of bleeding in a narrow anatomical space or a high-risk part.

The present invention relates to a phytological composition as a hemostatic agent, for example for use in the treatment of wounds and / or bleeding lesions of the skin and / or mucous membranes. The phytological composition consists of a polysaccharide of Tremella fuciformis, an extract of leaves of Vitis vinifera, an extract of leaves of Astragalus membranaceus, an extract of Medicago sativa, an extract of Fucus vesiculosus, a powder of Spirulia platensis, an extract of root of Beta vulgaris and an extract of Polygonum cuspidatum. The present invention also relates to pharmaceutical formulations comprising said phytological composition together with suitable pharmaceutically acceptable excipients.

A surgical device includes a substrate and a first coating that covers at least a portion of the substrate. The first coating includes a first polymer. The first coating having antibiotics dispersed in the first polymer such that the first polymer releases the antibiotics as the first polymer degrades. A second coating covers at least a portion of the first coating. The second coating includes a second polymer. The second polymer includes an alginate. The second coating has a hemostatic agent dispersed in the second polymer such that the second polymer releases the hemostatic agent as the second polymer degrades. The hemostatic agent is selected from epinephrine, tranexamic acid, chitosan and oxidized regenerated cellulose. In some embodiments, systems and methods are disclosed.

The invention discloses an acute gastrorrhagia hemostatic agent based on a gardenia carbon nano composite material and a preparation method of the acute gastrorrhagia hemostatic agent, and belongs to the technical field of biological medicines. According to the preparation method disclosed by the invention, the gardenia carbon nano composite material is prepared through nanocrystallization transformation, and the average particle size is 2.35 nm + / -0.56 nm. Mouse tail cutting hemostasis and capillary experiments prove that the gardenia charcoal nano composite material has the effects of promoting hemostasis and blood coagulation, and the hemostasis time and the blood coagulation time can be remarkably shortened; through construction of a rat blood-heat gastrorrhagia model, it is verified that the gardenia charcoal nano composite material has a remarkable hemostatic effect; and zebra fish verifies that the gardenia carbon nano composite material can protect gastrointestinal mucosa from being damaged, specifically, the area of a small intestinal cavity is reduced, and the number of neutrophils in the intestinal tract is reduced. The gardenia carbon nano composite material provided by the invention can be used for preparing a medicine for promoting blood coagulation and / or hemostasis, a hemostatic for acute gastrorrhagia and a medicine for relieving gastrointestinal mucosal injury.

The present invention relates to a powder type hemostatic composition and method for preparing the same, and more specifically, to powder aggregate having porosity obtained by combining powder of biocompatible hemostatic material with a binder and a method for preparing the same, and a powder type hemostatic composition which comprises the powder aggregate and shows improved hemostatic performance as compared with simple powder hemostatic agents, and can be used to a large surface area for hemostasis, or to narrow, thin or other sites to which approach for hemostasis is difficult.